PDF herunterladen
CC BY-NC-ND 4.0 · Thromb Haemost 2018; 118(11): e1-e2
DOI: 10.1055/s-0039-3400530
Erratum

Erratum: Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice

Derek Weycker
1   Policy Analysis Inc. (PAI), Brookline, Massachusetts, United States
,
Xiaoyan Li
2   Bristol-Myers Squibb, Lawrenceville, New Jersey, United States
,
Gail DeVecchis Wygant
2   Bristol-Myers Squibb, Lawrenceville, New Jersey, United States
,
Theodore Lee
3   Pfizer Inc., New York, New York, United States
,
Melissa Hamilton
2   Bristol-Myers Squibb, Lawrenceville, New Jersey, United States
,
Xuemei Luo
4   Pfizer Inc., Groton, Connecticut, United States
,
Lien Vo
2   Bristol-Myers Squibb, Lawrenceville, New Jersey, United States
,
Jack Mardekian
3   Pfizer Inc., New York, New York, United States
,
Xianying Pan
5   Bristol-Myers Squibb, Wallingford, Connecticut, United States
,
Leah Burns
2   Bristol-Myers Squibb, Lawrenceville, New Jersey, United States
,
Mark Atwood
1   Policy Analysis Inc. (PAI), Brookline, Massachusetts, United States
,
Ahuva Hanau
1   Policy Analysis Inc. (PAI), Brookline, Massachusetts, United States
,
Alexander T. Cohen
6   Guy's and St. Thomas' Hospitals, London, United Kingdom
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
 
 als PDF herunterladen Lizenzen und Reprints

Originalartikel zu diesem Erratum:

Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical PracticeThromb Haemost 2018; 118(11): 1951-1961
DOI: 10.1055/s-0038-1673689

    The authors have brought to the publisher's attention that there were some errors in [Fig. 1] of the article and [Table 1] of the [Supplementary Material] published in the above article in Thrombosis and Haemostasis, Volume 118, Number 8, 2018 (DOI: 1 10.1055/s-0038-1673689). The corrected figure and table appear as follows:

    Zoom Image
    Fig. 1 Selection of patients receiving apixaban or warfarin as outpatient therapy for VTE. IVCF, inferior vena cava filter; OAC, oral anticoagulant; PAC, parenteral anticoagulant; VTE, venous thromboembolism.

    #

    Die Autoren geben an, dass kein Interessenkonflikt besteht.

    Supplementary Material


    Address for correspondence

    Derek Weycker, PhD
    Policy Analysis Inc. (PAI)
    Four Davis Court, Brookline, Massachusetts, 02445
    United States   

    Publikationsverlauf

    Artikel online veröffentlicht:
    27. Januar 2020

    © 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

    Georg Thieme Verlag KG
    Rüdigerstraße 14, 70469 Stuttgart, Germany


       Lizenzen und Reprints
    Zoom Image
    Fig. 1 Selection of patients receiving apixaban or warfarin as outpatient therapy for VTE. IVCF, inferior vena cava filter; OAC, oral anticoagulant; PAC, parenteral anticoagulant; VTE, venous thromboembolism.